ISSN: 1351-0088

Journal Home

Journal Guideline

Endocrine-Related Cancer Q1 Unclaimed

BioScientifica Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Endocrine-Related Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 146. It has an SJR impact factor of 1,331 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,331.

Endocrine-Related Cancer focuses its scope in these topics and keywords: breast, serine, phosphorylation, prostate, sdhxrelated, response, receptor, pathway, pikaktmtor, pheochromocytoma, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Endocrinology (Q1) Endocrinology, Diabetes and Metabolism (Q1) Endocrinology, Diabetes and Metabolism (Q1) Oncology (Q1) Cancer Research (Q2)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

1,331

SJR Impact factor

146

H Index

108

Total Docs (Last Year)

282

Total Docs (3 years)

6365

Total Refs

1135

Total Cites (3 years)

275

Citable Docs (3 years)

4.11

Cites/Doc (2 years)

58.94

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

Estrogen receptor beta in breast cancer.

Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.

Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: a preliminary report.

Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.

Molecular targets in breast cancer: current status and future directions.

Identification and validation of cell surface antigens for antibody targeting in oncology

Progress in breast cancer chemoprevention.

A new form of familial multi-nodular goitre with progression to differentiated thyroid cancer

Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.

Oestrogens and prostate cancer.

Methylation mechanisms in pituitary tumorigenesis.

Deregulated expression of selected histone methylases and demethylases in prostate carcinoma

SHOW MORE ARTICLES

Proteomics study of serum exosomes from papillary thyroid cancer patients

How to target estrogen receptor-negative breast cancer?

Targeted radionuclide therapy for neuroendocrine tumours.

BRCA1/2 carriers and endocrine risk modifiers.

Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.

Epigenetic change in pituitary tumorigenesis.

Prostate cancer susceptibility genes: lessons learned and challenges posed.

Serum oestradiol and breast cancer risk.

Highlights of the biology of endocrine tumours of the gut and pancreas.

Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors

Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.

The Krv¬?ppel-like transcription factor 6 gene in sporadic pituitary tumours.